Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Total Liabilities

Last Annual Value

26.52M

3-Year CAGR

15%

5-Year CAGR

17%

10-Year CAGR

-15%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Total Liabilities

SERA · NASDAQ
CompanyTotal Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
26.52M
1.6%25.7%N/A 
41.65M
17.8%15.6%N/A
52.01M
-0.2%28.7%19.3%
8.02M
24.1%21.5%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
91.23M
-21.0%2.0%N/A
20.27M
-28.8%6.5%18.4%
57.22M
1.7%-9.5%28.7%
13.95M
15.7%-3.1%13.4%
295.48M
31.3%46.1%42.6%
29.51M
-0.1%47.3%N/A
6.42M
2.7%-2.1%17.0%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245